| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5647578 | The Journal of Allergy and Clinical Immunology: In Practice | 2017 | 8 Pages |
Abstract
Consistent with previous data, our observations suggest that patients who experience grade 1 reactions to rituximab can be safely rechallenged the same day. A grade 3 or 4 reaction should prompt referral to an allergy specialist for risk assessment before additional rituximab administration. Further research is needed to understand the optimal management of patients with grade 2 reactions.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Amy S. MD, Iris M. MD, Timothy MD, Ephraim MD, Aleena MD,